Matching Items (4)
128040-Thumbnail Image.png
Description

The brain is a common site of metastatic disease in patients with breast cancer, which has few therapeutic options and dismal outcomes. The purpose of our study was to identify common and rare events that underlie breast cancer brain metastasis. We performed deep genomic profiling, which integrated gene copy number,

The brain is a common site of metastatic disease in patients with breast cancer, which has few therapeutic options and dismal outcomes. The purpose of our study was to identify common and rare events that underlie breast cancer brain metastasis. We performed deep genomic profiling, which integrated gene copy number, gene expression and DNA methylation datasets on a collection of breast brain metastases. We identified frequent large chromosomal gains in 1q, 5p, 8q, 11q, and 20q and frequent broad-level deletions involving 8p, 17p, 21p and Xq. Frequently amplified and overexpressed genes included ATAD2, BRAF, DERL1, DNMTRB and NEK2A. The ATM, CRYAB and HSPB2 genes were commonly deleted and underexpressed. Knowledge mining revealed enrichment in cell cycle and G2/M transition pathways, which contained AURKA, AURKB and FOXM1. Using the PAM50 breast cancer intrinsic classifier, Luminal B, Her2+/ER negative, and basal-like tumors were identified as the most commonly represented breast cancer subtypes in our brain metastasis cohort. While overall methylation levels were increased in breast cancer brain metastasis, basal-like brain metastases were associated with significantly lower levels of methylation. Integrating DNA methylation data with gene expression revealed defects in cell migration and adhesion due to hypermethylation and downregulation of PENK, EDN3, and ITGAM. Hypomethylation and upregulation of KRT8 likely affects adhesion and permeability. Genomic and epigenomic profiling of breast brain metastasis has provided insight into the somatic events underlying this disease, which have potential in forming the basis of future therapeutic strategies.

ContributorsSalhia, Bodour (Author) / Kiefer, Jeff (Author) / Ross, Julianna T. D. (Author) / Metapally, Raghu (Author) / Martinez, Rae Anne (Author) / Johnson, Kyle N. (Author) / DiPerna, Danielle M. (Author) / Paquette, Kimberly M. (Author) / Jung, Sungwon (Author) / Nasser, Sara (Author) / Wallstrom, Garrick (Author) / Tembe, Waibhav (Author) / Baker, Angela (Author) / Carpten, John (Author) / Resau, Jim (Author) / Ryken, Timothy (Author) / Sibenaller, Zita (Author) / Petricoin, Emanuel F. (Author) / Liotta, Lance A. (Author) / Ramanathan, Ramesh K. (Author) / Berens, Michael E. (Author) / Tran, Nhan L. (Author) / Biodesign Institute (Contributor)
Created2014-01-29
128418-Thumbnail Image.png
Description

We used DNA content flow cytometry followed by oligonucleotide array based comparative genomic hybridization to survey the genomes of 326 tumors, including 41 untreated surgically resected triple negative breast cancers (TNBC). A high level (log2ratio ≥1) 9p24 amplicon was found in TNBC (12/41), glioblastomas (2/44), and colon carcinomas (2/68). The

We used DNA content flow cytometry followed by oligonucleotide array based comparative genomic hybridization to survey the genomes of 326 tumors, including 41 untreated surgically resected triple negative breast cancers (TNBC). A high level (log2ratio ≥1) 9p24 amplicon was found in TNBC (12/41), glioblastomas (2/44), and colon carcinomas (2/68). The shortest region of overlap for the amplicon targets 9p24.1 and includes the loci for PD-L1, PD-L2, and JAK2 (PDJ amplicon). In contrast this amplicon was absent in ER+ (0/8) and HER2+ (0/15) breast tumors, and in pancreatic ductal adenocarcinomas (0/150). The PDJ amplicon in TNBCs was correlated with clinical outcomes in group comparisons by two-sample t-tests for continuous variables and chi-squared tests for categorical variables. TNBC patients with the PDJ amplicon had a worse outcome with worse disease-free and overall survival. Quantitative RT-PCR confirmed that the PDJ amplicon in TNBC is associated with elevated expression of JAK2 and of the PD-1 ligands. These initial findings demonstrate that the PDJ amplicon is enriched in TNBC, targets signaling pathways that activate the PD-1 mediated immune checkpoint, and identifies patients with a poor prognosis.

ContributorsBarrett, Michael T. (Author) / Anderson, Karen (Author) / Lenkiewicz, Elizabeth (Author) / Andreozzi, Mariacarla (Author) / Cunliffe, Heather E. (Author) / Klassen, Christine L. (Author) / Dueck, Amylou C. (Author) / McCullough, Ann E. (Author) / Reddy, Srikanth K. (Author) / Ramanathan, Ramesh K. (Author) / Northfelt, Donald W. (Author) / Pockaj, Barbara A. (Author) / Biodesign Institute (Contributor)
Created2015-07-03
129084-Thumbnail Image.png
Description

Background: Recent advances in the treatment of cancer have focused on targeting genomic aberrations with selective therapeutic agents. In rare tumors, where large-scalec linical trials are daunting, this targeted genomic approach offers a new perspective and hope for improved treatments. Cancers of the ampulla of Vater are rare tumors that comprise

Background: Recent advances in the treatment of cancer have focused on targeting genomic aberrations with selective therapeutic agents. In rare tumors, where large-scalec linical trials are daunting, this targeted genomic approach offers a new perspective and hope for improved treatments. Cancers of the ampulla of Vater are rare tumors that comprise only about 0.2% of gastrointestinal cancers. Consequently, they are often treated as either distal common bile duct or pancreatic cancers.

Methods: We analyzed DNA from a resected cancer of the ampulla of Vater and whole blood DNAfrom a 63 year-old man who underwent a pancreaticoduodenectomy by whole genomesequencing, achieving 37× and 40× coverage, respectively. We determined somatic mutations and structural alterations.

Results: We identified relevant aberrations, including deleterious mutations of KRAS and SMAD4 as well as a homozygous focal deletion of the PTEN tumor suppressor gene. These findings suggest that these tumors have a distinct oncogenesis from either common bile duct cancer or pancreatic cancer. Furthermore, this combination of genomic aberrations suggests a therapeutic context for dual mTOR/PI3K inhibition.

Conclusions: Whole genome sequencing can elucidate an oncogenic context and expose potential therapeutic vulnerabilities in rare cancers.

ContributorsDemeure, Michael J. (Author) / Craig, David W. (Author) / Sinari, Shripad (Author) / Moses, Tracy M. (Author) / Christoforides, Alexis (Author) / Dinh, Jennifer (Author) / Izatt, Tyler (Author) / Aldrich, Jessica (Author) / Decker, Ardis (Author) / Baker, Angela (Author) / Cherni, Irene (Author) / Watanabe, April (Author) / Koep, Lawrence (Author) / Lake, Douglas (Author) / Hostetter, Galen (Author) / Trent, Jeffrey M. (Author) / Von Hoff, Daniel D. (Author) / Carpten, John D. (Author) / College of Liberal Arts and Sciences (Contributor)
Created2012-07-04
128865-Thumbnail Image.png
Description

Pancreatic adenocarcinoma (PAC) is among the most lethal malignancies. While research has implicated multiple genes in disease pathogenesis, identification of therapeutic leads has been difficult and the majority of currently available therapies provide only marginal benefit. To address this issue, our goal was to genomically characterize individual PAC patients to

Pancreatic adenocarcinoma (PAC) is among the most lethal malignancies. While research has implicated multiple genes in disease pathogenesis, identification of therapeutic leads has been difficult and the majority of currently available therapies provide only marginal benefit. To address this issue, our goal was to genomically characterize individual PAC patients to understand the range of aberrations that are occurring in each tumor. Because our understanding of PAC tumorigenesis is limited, evaluation of separate cases may reveal aberrations, that are less common but may provide relevant information on the disease, or that may represent viable therapeutic targets for the patient. We used next generation sequencing to assess global somatic events across 3 PAC patients to characterize each patient and to identify potential targets. This study is the first to report whole genome sequencing (WGS) findings in paired tumor/normal samples collected from 3 separate PAC patients. We generated on average 132 billion mappable bases across all patients using WGS, and identified 142 somatic coding events including point mutations, insertion/deletions, and chromosomal copy number variants. We did not identify any significant somatic translocation events. We also performed RNA sequencing on 2 of these patients' tumors for which tumor RNA was available to evaluate expression changes that may be associated with somatic events, and generated over 100 million mapped reads for each patient. We further performed pathway analysis of all sequencing data to identify processes that may be the most heavily impacted from somatic and expression alterations. As expected, the KRAS signaling pathway was the most heavily impacted pathway (P<0.05), along with tumor-stroma interactions and tumor suppressive pathways. While sequencing of more patients is needed, the high resolution genomic and transcriptomic information we have acquired here provides valuable information on the molecular composition of PAC and helps to establish a foundation for improved therapeutic selection.

ContributorsLiang, Winnie S. (Author) / Craig, David W. (Author) / Carpten, John (Author) / Borad, Mitesh J. (Author) / Demeure, Michael J. (Author) / Weiss, Glen J. (Author) / Izatt, Tyler (Author) / Sinari, Shripad (Author) / Christoforides, Alexis (Author) / Aldrich, Jessica (Author) / Kurdoglu, Ahmet (Author) / Barrett, Michael (Author) / Phillips, Lori (Author) / Benson, Hollie (Author) / Tembe, Waibhav (Author) / Braggio, Esteban (Author) / Kiefer, Jeffrey A. (Author) / Legendre, Christophe (Author) / Posner, Richard (Author) / Hostetter, Galen H. (Author) / Baker, Angela (Author) / Egan, Jan B. (Author) / Han, Haiyong (Author) / Lake, Douglas (Author) / Stites, Edward C. (Author) / Ramanathan, Ramesh K. (Author) / Fonseca, Rafael (Author) / Stewart, A. Keith (Author) / Von Hoff, Daniel (Author) / College of Liberal Arts and Sciences (Contributor)
Created2012-10-10